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Clinical trials have shown that at least 40% of patients with chronic 
hepatitis C (HCV) are able to achieve sustained virologic response 
(SVR) with peginterferon-alfa/ribavirin (PegIFN/RBV) therapy along with 
adequate medical and psychiatric support.  Those with a history of 
mental illness or multiple medical comorbidities are often excluded from 
clinical trials1,2.  Hence, SVR is achieved less often in clinical practice.  
We proposed that an integrated, multidisciplinary approach to PegIFN/
RBV therapy would result in SVR rates similar to those of clinical trials in 
a medically and psychiatrically complex cohort of patients.
Introduction: 
A pilot Hepatitis C Clinic was established in 2004, staffed by internal 
medicine residents, an attending gastroenterologist and psychiatrist, and 
a registered-nurse coordinator.  All patients were underinsured/uninsured 
and underwent treatment for HCV with PegIFN/RBV combination 
therapy according to evidence-based protocols within the confines of 
managed-care formularies. Charts were retrospectively abstracted for 
demographics and baseline characteristics, virologic response, side 
effects, and reasons for discontinuation or non-initiation of therapy.
Methods: 
Forty-eight patients were evaluated.  None were co-infected with human 
immunodeficiency virus (HIV).  Twenty-two (46%) were not treated, and 
twenty-six (54%) were treated.  Of the patients who were treated, twenty-
two (84%) were genotype 1, three (12%) were genotype 2b, and one (3%) 
was genotype 4a.  
Results:
Despite a patient population with mostly 
genotype 1 HCV and significant medical/
psychiatric comorbidities, a similar number of 
patients achieved ETR/SVR as compared to 
those in clinical trials1,2.  These data suggest 
that an integrative medicine practice can safely 
and effectively manage PegIFN/RBV therapy 
and serve as a model to expand access to 
antiviral therapy for many individuals with 
chronic HCV.  Additionally, by incorporating a 
dedicated group of internal medicine residents, 
the pool of capable and willing providers of 
PegIFN/RBV therapy will be expanded.
Conclusions:
Table 2: Reasons not to 
treat with PegIFN/RBV
 Personal Choice 6 (27%)
 Unstable Psychiatric Illness 6 (27%)
Comorbidities 4 (18%)
Substance Abuse 2 (9%)
 Viral Clearance 2 (9%)
Lack of follow up 1 (4%)
Minimal Fibrosis 1 (4%)
Table 3: Outcomes of
PegIFN/RBV  n=26
 Nonresponders (NR) 5 (19%)
 Early Viralogic Response (EVR) 13 (50%)
End of Treatment Response (ETR) 12 (46%)
Sustained Viralogic Response (SVR) 8/23 (34%)*
Relapse after ETR 2 (7%)
Dropouts 8 (30%)
*  Three patients were omitted from the total number for evaluation 
of SVR.  Two patients had not reached 24 weeks beyond the end 
of treatment.  One patient was lost to follow up.
Table 4: Side Effects
Hyperuricemia 12 (46%)






Table 5: Reasons for
Discontinuation of PegIFN/RBV
 Side Effects 6 (23%)
 Viralogic Nonresponse 5 (19%)
Psychiatric Side Effects 1 (3%)
Poor Adherence 1 (3%)
Ongoing Substance Abuse 1 (3%)
Incarceration 1 (3%)
Table 1: Demographic
data for all patients 
 Gender Male         15 (31%)Female     33 (69%)
 Average Age 45.0 years
Average Weight of 
Treated Patients 191.3 lbs.
Baseline Viral Load
> 400,000 IU   29 (60%)
< 400,000 IU   16 (33%)
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